Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;17(2):130-136.
doi: 10.1159/000514891. Epub 2021 May 25.

Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving Anthracycline-Cyclophosphamide-Based Chemotherapy

Jörg Schilling  1 , Christian M Kurbacher  2 , Claus Hanusch  3 , Steffi Busch  4 , Martin Holländer  5 , Janine Kreiss-Sender  6 , Daniela Rezek  7 , Elisa Flahaut  8 , Meinolf Karthaus  9   10
Affiliations

Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving Anthracycline-Cyclophosphamide-Based Chemotherapy

Jörg Schilling et al. Breast Care (Basel). 2022 Apr.

Abstract

Introduction: In a prospective non-interventional study involving 2,173 patients, we showed that use of the oral fixed combination of netupitant 300 mg and palonosetron 0.5 mg (NEPA) for prevention of chemotherapy (Ctx)-induced nausea and vomiting has beneficial effects on the quality of life (QoL) of patients with various types of cancers receiving highly or moderately emetogenic Ctx. Here, we report on the effects on QoL, effectiveness, and tolerability of NEPA in patients with breast cancer exposed to anthracycline-cyclophosphamide (AC)-based Ctx.

Methods: This is a post hoc subanalysis of a prospective non-interventional study in 1,197 patients with breast cancer receiving up to 3 cycles of doxorubicin or epirubicin plus cyclophosphamide and NEPA. NEPA administration was per the summary of product characteristics.

Results: In cycle 1 of Ctx, a large proportion of patients (84%) reported "no impact on daily life" (NIDL) due to vomiting; 53% of patients reported NIDL due to nausea. The complete response rate was 86/88/81% in the acute/delayed/overall phase in cycle 1, and NEPA was well tolerated throughout the study.

Conclusion: The real-world beneficial effects of NEPA prophylaxis on QoL were confirmed for patients with breast cancer receiving AC. NEPA was effective with a good safety profile in this patient population in clinical practice.

Keywords: Antiemetic; Breast cancer; Chemotherapy-induced nausea and vomiting; NEPA; Netupitant; Palonosetron; Real-world.

PubMed Disclaimer

Conflict of interest statement

J.S.: honoraria, travel expenses, RIEMSER Pharma GmbH. C.M.K.: honoraria, Amgen, Eli Lilly, Novartis, Mundipharma, Pfizer, PharmaMar, RIEMSER, Roche, Tesaro; consulting or advisory role, Amgen, Axios, Eli Lilly, Hilotherm, Mundipharma, NewCo, Novartis, Pfizer, RIEMSER, Roche, Tesaro; research funding, AstraZeneca, Axios, MSD Sharp & Dohme (Merck), NewCo, Novartis, Pfizer, PharmaMar, RIEMSER, Seattle Genetics, Immunomedics; travel, accommodations, expenses, Amgen, Hexal, Immunomedics, Pfizer, PharmaMar, Tesaro, Teva Oncology. C.H.: advisory board, AstraZeneca, Lilly, Pfizer, Roche. S.B.: lectures, studies and support for congress participation, Amgen, Roche, Novartis, Pfizer, Riemser, Lilly, Clovis, GSK, Onkovis, AstraZeneca, MSD. M.H.: honoraria, Pfizer, AstraZeneca, iOMEDICO, MMF, Amgen; research funding, RIEMSER, Indivumed. J.K.-S. and D.R.: nothing to disclose. E.F.: RIEMSER employee. M.K.: ad board, travel grant, Helsinn Healthcare, RIEMSER Pharma GmbH.

Figures

Fig. 1
Fig. 1
Relative frequencies of patients experiencing no influence on daily life activities due to nausea, vomiting, or combined nausea and vomiting, by cycle: subanalysis population. NIDL, no impact on daily life.
See this image and copyright information in PMC

References

    1. Brambilla C, De Lena M, Bonadonna G. Combination chemotherapy with adriamycin (NSC-123127) in metastatic mammary carcinoma. Cancer Chemother Rep. 1974 Mar-Apr;58((2)):251–3. - PubMed
    1. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007 May;15((5)):497–503. - PubMed
    1. Richardson LC, Wang W, Hartzema AG, Wagner S. The role of health-related quality of life in early discontinuation of chemotherapy for breast cancer. Breast J. 2007 Nov-Dec;13((6)):581–7. - PubMed
    1. Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017 Jul;318((2)):197–8. - PMC - PubMed
    1. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Breast cancer. Version 6. 2020.